The Antibody Hit Generation and Screening Market Size is predicted to grow at an 9.78% CAGR during the forecast period for 2024-2031.
Antibody hit generation and screening is a vital step in developing therapeutic antibodies, focusing on identifying and selecting candidates that bind to a target antigen with high affinity and specificity. This process leverages various technologies like hybridoma technology, phage display, yeast display, ribosome display, and computational tools to create and screen extensive libraries of antibody variants. The goal is to identify the most promising candidates for further development, which are crucial in advancing antibody-based medicines for treating various diseases.
The application of antibody hit generation and screening is particularly significant in treating cancer, autoimmune diseases, and infectious diseases. By identifying antibodies that target specific antigens associated with these conditions, researchers can develop therapies that are more effective and have fewer side effects. The increasing prevalence of chronic diseases globally is a major driving factor in this market. As the incidence of conditions like cancer, autoimmune disorders, and infectious diseases rises, the demand for effective and targeted therapies grows. Antibody-based medicines developed through hit generation and screening have the potential to meet this need and improve patient outcomes.
Competitive Landscape
Some of the Key Players in Antibody Hit Generation and Screening Market:
- Hoffmann-La Roche Ltd.
- AbbVie
- Pfizer
- AstraZeneca
- Novartis
- Eli Lilly
- WuXi AppTec
- Charles River Laboratories
- Syngenta
- BioLegend
- Creative Biolabs
- Eurofins CDMO
- AbCellera
- MorphoSys
- Evelo Biosciences
- Icos Therapeutics
- Argenx
- Kymab
- Alnylam Pharmaceuticals
- SAb Biotherapeutics
Market Segmentation:
The antibody hit generation and screening market is segmented by application, technologies, antibody type. By application the market is segmented into cancer, autoimmune diseases, infectious diseases, by technologies market is categorized into hit generation, phage display, yeast display, ribosome display, b-cell hybridoma technology, computational tools, screening. By antibody type market is categorized into humanized antibody, human antibody, chimeric antibody, murine antibody.
Phage display is Expected to Drive the Antibody Hit Generation and Screening Market
Phage display is a key technology in antibody hit generation and screening, known for its efficiency in identifying high-affinity antibodies from vast libraries. It enables the creation of billions of unique antibody variants, each linked to a bacteriophage, allowing for straightforward screening in a single experiment. The technology supports high-throughput screening (HTS) through a process called "biopanning," where antibodies are rapidly selected based on their binding strength to target antigens. Its customization and versatility, including the ability to construct libraries from different species and integrate with other technologies, make phage display an essential tool in modern drug discovery.
Humanized Antibody is Growing at the Highest Rate in the Antibody Hit Generation and Screening Market.
Humanized antibodies are driving growth in the antibody hit generation and screening market due to their enhanced safety and efficacy, reduced risk of immune reactions, and suitability for targeted therapies, particularly in treating cancer and autoimmune disorders. The rising demand for such therapies, combined with advancements in antibody engineering technologies like phage display and computational design, has accelerated the development of high-affinity humanized antibodies. Additionally, the rapid expansion of the biopharmaceutical industry, with increasing investments in R&D, is fueling the demand for humanized antibody discovery and screening.
Regionally, North America Led the Antibody Hit Generation and Screening Market.
North America is a hub for pharmaceutical and biotech firms, driving innovation in antibody discovery. Significant investments in R&D fuel advancements in antibody engineering and screening technologies, supported by cutting-edge methodologies like phage display and hybridoma technologies. Favorable regulatory frameworks further encourage the development and commercialization of new antibody-based therapies. Additionally, the rising demand for personalized medicine in the region increases the need for diverse antibody libraries tailored to specific patient needs.
Antibody Hit Generation and Screening Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 9.78 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Application, Technologies, Antibody Type and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
F. Hoffmann-La Roche Ltd., AbbVie, Pfizer, AstraZeneca, Novartis, Eli Lilly, WuXi AppTec, Charles River Laboratories, Syngenta, BioLegend, Creative Biolabs, Eurofins CDMO, AbCellera, MorphoSys, Evelo Biosciences, Icos Therapeutics, Argenx, Kymab, Alnylam Pharmaceuticals, SAb Biotherapeutic |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
